
CLAIMS

1. A compound having Structural Formula (I):



(I),

or a pharmaceutically acceptable salt thereof, wherein:

X is $C(R^2)$, wherein R^2 is

$-(C_0-C_6$ alkylene)-heterocyclyl, wherein the heterocyclyl is unsubstituted or substituted on a nitrogen atom with $-(C_1-C_6$ alkyl),

$-(C_0-C_6$ alkylene)-carbocyclyl or

$-(C_1-C_6)$alkyl substituted with $NR^BR^{B'}$;

R^1 is selected from hydrogen, fluoro, chloro, CF_3 and OCF_3;

each of R^3, R^5 and R^6 is independently selected from hydrogen, halo, $-(C_1-C_6$ alkyl), $-OR^A$, $-C(O)NR^BR^{B'}$, $NR^BR^{B'}$, $S(O)_{0-2}R^C$, $-(C_0-C_6$ alkylene)-carbocyclyl, and $-(C_0-C_6$ alkylene)-heterocyclyl; or

R^4 is selected from hydrogen, methyl, ethyl, or propyl;

$R^{4'}$ is selected from hydrogen, ethyl, propyl, $-S(O)_2CH_3$, cyclopropyl, $-C(O)CH_3$ or $-C(O)CH_2N(CH_3)_2$;

$R^{6'}$ is selected from hydrogen, $-(C_1-C_6$ alkyl) and $-(C_3-C_6$ cycloalkyl);

each R^A is independently selected from hydrogen, $-(C_1-C_6$ alkyl), $-(C_0-C_6$ alkylene)-carbocyclyl, $-(C_0-C_6$ alkylene)-heterocyclyl, $-C(O)-(C_1-C_6$ alkyl), $-C(O)-(C_0-C_6$ alkylene)-carbocyclyl, $-C(O)-(C_0-C_6$ alkylene)-heterocyclyl, and $-C(O)N(R^D)(R^E)$;

each R^B and each $R^{B'}$ is independently selected from hydrogen, $-(C_1-C_6$ alkyl), $-(C_1-C_6$ haloalkyl), $-(C_0-C_6$ alkylene)-carbocyclyl, $-(C_0-C_6$ alkylene)-heterocyclyl, $-S(O)_{1-2}-(C_1-C_6$ alkyl), $-S(O)_{1-2}-(C_0-C_6$ alkylene)-carbocyclyl, $-S(O)_{1-2}-(C_0-C_6$ alkylene)-heterocyclyl, $-C(O)-(C_1-C_6$ alkyl), $-C(O)-(C_0-C_6$ alkylene)-carbocyclyl, -C(O)H, $-C(O)-(C_0-C_6$ alkylene)-heterocyclyl, and $-C(O)-(C_0-C_6$ alkylene)-$N(R^D)(R^E)$;

each R^C is independently selected from -(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-carbocyclyl and -(C_0-C_6 alkylene)-heterocyclyl; and

each R^D and each R^E is independently selected from hydrogen, -(C_1-C_6 alkyl), -(C_0-C_6 alkylene)-carbocyclyl, and -(C_0-C_6 alkylene)-heterocyclyl,

wherein:

any alkyl, or alkylene portion of R^2, R^3, R^4, $R^{4'}$, R^5, R^6 is optionally and independently substituted with one or more substituents independently selected from halo, =O, OR^A, $NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any alkyl or alkylene portion of $R^{6'}$, R^A, or R^C, is optionally and independently substituted with one or more fluoro;

any carbocyclyl or heterocyclyl portion of any of R^2, R^3, R^5, R^6 is optionally and independently substituted on a carbon atom with one or more substituents independently selected from halo, =O, C_1-C_4 fluoroalkyl, C_1-C_4 alkyl, -(C_0-C_6 alkylene)-(C_3-C_{10} carbocyclyl), -(C_0-C_6 alkylene)-(4-13 membered heterocyclyl), OR^A, -(C_0-C_6 alkylene)-$NR^BR^{B'}$, and $S(O)_{0-2}R^C$;

any heterocyclyl portion of any of R^2, R^3, R^5, R^6 is optionally and independently substituted on a substitutable nitrogen atom with R^F;

each R^F is independently selected from -(C_1-C_6 alkyl), -(C_1-C_6 haloalkyl), -(C_1-C_6 hydroxyalkyl), -(C_0-C_6 alkylene)-carbocyclyl, -(C_0-C_6 alkylene)-heterocyclyl, -$S(O)_{1-2}$-(C_1-C_6 alkyl), -$S(O)_{1-2}$-(C_0-C_6 alkylene)-carbocyclyl, -$S(O)_{1-2}$-(C_0-C_6 alkylene)-heterocyclyl, -C(O)-(C_1-C_6 alkyl), -C(O)-(C_0-C_6 alkylene)-carbocyclyl, -C(O)H, -C(O)-(C_0-C_6 alkylene)-heterocyclyl, -(C_0-C_6 alkylene)-$C(O)_2$-(C_1-C_6 alkyl), -(C_1-C_6 alkylene)-$NR^BR^{B'}$ and -C(O)N(R^D)(R^E);

any carbocyclyl or heterocyclyl portion of R^A, R^B, $R^{B'}$, R^C, R^D, R^E, R^F, any cycloalkyl portion of $R^{6'}$, or any substituent of R^2, R^3, R^5, R^6 is optionally and independently substituted on a carbon atom with one or more substituents independently selected from fluoro, chloro, C_1-C_4 alkyl, C_1-C_4 fluoroalkyl, -O-C_1-C_4 alkyl, -O-C_1-C_4 fluoroalkyl, =O, -OH, -NH_2, -NH(C_1-C_4 alkyl), and -N(C_1-C_4 alkyl)$_2$; and

any heterocyclyl portion of R^A, R^B, $R^{B'}$, R^C, R^D, R^E, R^F, or any heterocyclyl substituent of R^2, R^3, R^5, or R^6 is optionally substituted on a substitutable nitrogen atom with -C_1-C_4 alkyl, or -$S(O)_{1-2}$-(C_1-C_4 alkyl).

2. The compound of claim 1, wherein each of R^5, R^6 and $R^{6'}$ is hydrogen.

3. The compound of claim 1 or claim 2, wherein:

R^C is -(C_1-C_6 alkyl); and

each of R^D and R^E is independently selected from hydrogen and -(C_1-C_6 alkyl).


4. The compound of any one of claims 1 to 3, wherein R^3 is selected from hydrogen and -$N(R^B)(R^{B'})$, wherein R^B is hydrogen.

5. The compound of claim 1, wherein R^2 is pyrrolidinyl optionally substituted on a nitrogen atom with C_1-C_4 alkyl or benzyl.

6. The compound of any one of claims 1-5, wherein:

R^3 is selected from hydrogen and -$N(R^B)(R^{B'})$, wherein R^B is hydrogen and $R^{B'}$ is -C(O)-(C_0-C_6 alkylene)-heterocyclyl or -C(O)-(C_0-C_6 alkylene)-$N(R^D)(R^E)$.


7. The compound of claim 6, wherein R^3 is selected from hydrogen




and .

8. A compound selected from any one of the following compounds:


S4-14-1 (diastereomer A)




S4-14-2 (diastereomer A)





















S4-14-3 (diastereomer A)




S4-14-4 (diastereomer A)




S4-14-5-A (diastereomer A) S4-14-5-B (diastereomer B) 	S4-14-7 (diastereomer A) 
S4-14-8 (diastereomer A) 	S4-14-9 (diastereomer A) 
S4-14-10 (diastereomer A) 	S4-14-11 (diastereomer A) 
S4-14-12 (diastereomer A) 	S4-14-13 (diastereomer A) 
S4-14-14-A (diastereomer A) S4-14-14-B (diastereomer B) 	S4-14-16 (diastereomer A) 
S7-14-2-A (diastereomer A) 	S7-14-1-A (diastereomer A) S7-14-1-B (diastereomer B) 
S7-14-3-A (diastereomer A) 	S8-4-1 
S8-4-2 	S8-4-3 
S10-4-1 (single diastereomer) 	S10-4-2 (single diastereomer) 


S10-4-3 (single diastereomer)




S14-8-1




S14-8-2




S14-8-3-A (diastereomer A)
S14-8-3-B (diastereomer B)




S19-7-1-B (diastereomer B)




S19-7-2




S19-7-3-A (diastereomer A)
S19-7-3-B (diastereomer B)




S19-7-4-A (diastereomer A)
S19-7-4-B (diastereomer B)




S19-7-5-A (diastereomer A)
S19-7-5-B (diastereomer B)




S19-7-6




S19-7-7-A (diastereomer A)
S19-7-7-B (diastereomer B)




S20-4-1 (single diastereomer)




S20-4-2 (single diastereomer)



S20-4-3 (single diastereomer)



S20-4-4 (single diastereomer)



or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of any one of Claims 1-8.

10. A compound of any one of Claims 1-8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 9, for use in the treatment of an infection or colonization.

11. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism that grows intracellularly as part of its infection process.

12. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by a Gram-positive organism.

13. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 12, wherein the Gram-positive organism is selected from the class Bacilli; phylum Actinobacteria; and class Clostridia.

14. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 13, wherein the class Bacilli organism is selected from *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., *Bacillus* spp., and *Listeria* spp.

15. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 13, wherein the class phylum Actinobacteria organism is selected from *Propionibacterium* spp., *Corynebacterium* spp., *Nocardia* spp., and *Actinobacteria* spp.

16. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 13, wherein the class Clostridia organism is selected from *Clostridium* spp.

17. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by a Gram-negative organism.

18. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 17, wherein the Gram-negative organism is selected from the group consisting of *Enterobactericeae, Bacteroidetes, Vibrionaceae*, *Pasteurellaceae*, *Pseudomonadaceae*, *Neisseriaceae, Rickettsiae*, *Moraxellaceae* any species of *Proteeae, Acinetobacter* spp., *Helicobacter* spp., and *Campylobacter* spp.

19. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism selected from order Rickettsiales and order Chlamydiales.

20. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism selected from the phylum Chlamydiae and phylum Spriochaetales.

21. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 20, wherein the phylum Spriochaetales organism is selected from *Borrelia* spp. and *Treponema* spp.

22. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism selected from the class Mollicutes.

23. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 22, wherein the class Mollicutes organism is selected from *Mycoplasma* spp.

24. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 23, wherein *Mycoplasma* spp. is *Mycoplasma pneumoniae.*

25. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism selected from *Legionella* spp. and *Mycobacterium* spp.

26. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 25, wherein the *Mycobacterium* spp is *Mycobacterium tuberculosis.*

27. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by more than one organism.

28. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to one or more antibiotics.

29. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to tetracycline or any member of first and second generation of tetracycline antibiotics.

30. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to methicillin or any antibiotic in the β-lactam class.

31. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 30, wherein the β-lactam class is selected from second, third and fourth-generation cephalosporins.

32. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to a quinolone or fluoroquinolone.

33. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to tigecycline.

34. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to tetracycline.

35. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to methicillin.

36. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to vancomycin.

37. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 10, wherein the infection is caused by an organism resistant to an antimicrobial peptide or a biosimilar therapeutic treatment.

38. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 12, wherein the Gram-positive organism is selected from *S. aureus*, CoNS, *S. pneumoniae*, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.

39. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 17, wherein the Gram-negative organism is selected from selected from *H. influenza, M. catarrhalis* and *Legionella pneumophila*.

40. A compound of any one of Claims 1-8, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 9 for use in the treatment of a respiratory infection.

41. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 40, wherein the respiratory infection is Community-Acquired Bacterial Pneumonia (CABP).

42. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 40 or Claim 41, wherein the respiratory infection is caused by a bacterium selected from *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenza, M. catarrhalis* and *Legionella pneumophila.*


43. A compound of any one of Claims 1-8, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 9 for use in the treatment of a skin infection.

44. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 43, wherein the skin infection is an acute bacterial skin and skin structure infection (ABSSSI).

45. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 43 or Claim 44, wherein the skin infection is caused by a bacterium selected from *S. aureus*, CoNS, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.

CLAIMS

1. A compound having Structural Formula S4-14:



S4-14,

or a pharmaceutically acceptable salt thereof, wherein:

R^4 is -(C_1-C_6 alkyl); and

$R^{4'}$ is -(C_2-C_6 alkyl).


2. The compound of Claim 1, wherein:

R^4 is selected from methyl, ethyl and propyl; and


$R^{4'}$ is selected from ethyl and propyl.

3. A compound of Claim 1 selected from any one of the following compounds:


S4-14-5-A (diastereomer A)
S4-14-5-B (diastereomer B)




S4-14-7 (diastereomer A)




S4-14-8 (diastereomer A)




S4-14-9 (diastereomer A)




S4-14-10 (diastereomer A)



S4-14-11 (diastereomer A)



S4-14-14-A (diastereomer A)
S4-14-14-B (diastereomer B)



or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of any one of Claims 1-3.

5. A compound of any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 4, for use in the treatment of bacterial infection.

6. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism that grows intracellularly as part of its infection process.

7. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by a Gram-positive organism.

8. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 7, wherein the Gram-positive organism is selected from the class Bacilli; phylum Actinobacteria; and class Clostridia.

9. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 8, wherein the class Bacilli organism is selected from *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., *Bacillus* spp., and *Listeria* spp.

10. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 8, wherein the class phylum Actinobacteria organism is selected from *Propionibacterium* spp., *Corynebacterium* spp., *Nocardia* spp., and *Actinobacteria* spp.

11. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 8, wherein the class Clostridia organism is selected from *Clostridium* spp.

12. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by a Gram-negative organism.

13. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 12, wherein the Gram-negative organism is selected from the group consisting of *Enterobactericeae, Bacteroidetes, Vibrionaceae*, *Pasteurellaceae*, *Pseudomonadaceae*, *Neisseriaceae, Rickettsiae*, *Moraxellaceae* any species of *Proteeae, Acinetobacter* spp., *Helicobacter* spp., and *Campylobacter* spp.

14. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism selected from order Rickettsiales and order Chlamydiales.

15. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism selected from the phylum Chlamydiae and phylum Spriochaetales.

16. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 15, wherein the phylum Spriochaetales organism is selected from *Borrelia* spp. and *Treponema* spp.

17. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism selected from the class Mollicutes.

18. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 17, wherein the class Mollicutes organism is selected from *Mycoplasma* spp.

19. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 18, wherein *Mycoplasma* spp. is *Mycoplasma pneumoniae.*

20. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism selected from *Legionella* spp. and *Mycobacterium* spp.

21. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 20, wherein the *Mycobacterium* spp is *Mycobacterium tuberculosis.*

22. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by more than one organism.

23. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to one or more antibiotics.

24. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to tetracycline or any member of first and second generation of tetracycline antibiotics.

25. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to methicillin or any antibiotic in the β-lactam class.

26. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 25, wherein the β-lactam class is selected from second, third and fourth-generation cephalosporins.

27. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to a quinolone or fluoroquinolone.

28. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to tigecycline.

29. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to tetracycline.

30. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to methicillin.

31. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to vancomycin.

32. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 5, wherein the infection is caused by an organism resistant to an antimicrobial peptide or a biosimilar therapeutic treatment.

33. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 7, wherein the Gram-positive organism is selected from *S. aureus*, CoNS, *S. pneumoniae*, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.

34. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 12, wherein the Gram-negative organism is selected from selected from *H. influenza, M. catarrhalis* and *Legionella pneumophila.*

35. A compound of any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 4 for use in the treatment of a respiratory infection caused by bacteria.

36. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 35, wherein the respiratory infection is Community-Acquired Bacterial Pneumonia (CABP).

37. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 35 or Claim 36, wherein the respiratory infection is caused by a bacterium selected from *S. aureus*, *S. pneumoniae*, *S. pyogenes*, *H. influenza, M. catarrhalis* and *Legionella pneumophila.*

38. A compound of any one of Claims 1-3, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of Claim 4 for use in the treatment of a skin infection caused by bacteria.

39. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 38, wherein the skin infection is an acute bacterial skin and skin structure infection (ABSSSI).

40. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition as claimed in Claim 38 or Claim 39, wherein the skin infection is caused by a bacterium selected from *S. aureus*, CoNS, *S. pyogenes*, *S. agalactiae*, *E. faecalis* and *E. faecium*.

41. The compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition, as claimed in Claim 12, wherein the Gram-negative organism is *A. baumanii*.